NKI-AVL Biobank (for blood and blood products)

Published: 01-03-2010 Last updated: 04-05-2024

_

Ethical review Approved WMO

Status Pending

Health condition type Other condition

Study type Observational invasive

Summary

ID

NL-OMON32651

Source

ToetsingOnline

Brief title

NKI-AVL Biobank

Condition

- Other condition
- Miscellaneous and site unspecified neoplasms malignant and unspecified

Synonym

cancer

Health condition

kanker- en therapie-gerelateerde aandoeningen

Research involving

Human

Sponsors and support

Primary sponsor: Nederlands Kanker Instituut

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention Keyword: biobank, blood, DNA, serum **Outcome measures Primary outcome Secondary outcome Study description Background summary Study objective** Study design Study burden and risks

Contacts

Public

Nederlands Kanker Instituut

Plesmanlaan 121 1066 CX NL

Scientific

Nederlands Kanker Instituut

Plesmanlaan 121 1066 CX NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

- newly diagnosed patient, selected tumor types
- or healthy volunteer visiting NKI-AVL

Exclusion criteria

_

Study design

Design

Study type: Observational invasive

Intervention model: Other

Allocation: Non-randomized controlled trial

Masking: Open (masking not used)

Control: Active

Primary purpose: Other

Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-10-2009

Enrollment: 50000

Type: Anticipated

Ethics review

Approved WMO

Application type: First submission

Review commission: PTC Stichting het Nederlands Kanker Instituut - Antoni van

Leeuwenhoekziekenhuis (Amsterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL29873.031.09